pramipexole has been researched along with nicotine in 3 studies
Studies (pramipexole) | Trials (pramipexole) | Recent Studies (post-2010) (pramipexole) | Studies (nicotine) | Trials (nicotine) | Recent Studies (post-2010) (nicotine) |
---|---|---|---|---|---|
1,103 | 219 | 517 | 28,519 | 2,280 | 9,302 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Ciraulo, DA; Hennen, J; Jensen, JE; Ke, Y; Knapp, C; Kwak, T; Meyer, AA; Nassar, LE; Renshaw, PF; Sarid-Segal, O; Streeter, CC | 1 |
Domino, EF; Jutkiewicz, EM; Ohmura, Y; Zhang, A | 1 |
1 trial(s) available for pramipexole and nicotine
Article | Year |
---|---|
Prefrontal GABA levels in cocaine-dependent subjects increase with pramipexole and venlafaxine treatment.
Topics: Adult; Antidepressive Agents, Second-Generation; Antioxidants; Benzothiazoles; Cocaine-Related Disorders; Cyclohexanols; Double-Blind Method; Female; gamma-Aminobutyric Acid; Humans; Magnetic Resonance Spectroscopy; Male; Middle Aged; Nicotine; Pramipexole; Prefrontal Cortex; Protons; Retrospective Studies; Thiazoles; Time Factors; Venlafaxine Hydrochloride | 2005 |
2 other study(ies) available for pramipexole and nicotine
Article | Year |
---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Dopamine D1/5 and D2/3 agonists differentially attenuate somatic signs of nicotine withdrawal in rats.
Topics: Analysis of Variance; Animals; Behavior, Animal; Benzazepines; Benzothiazoles; Dopamine; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Implants; Injections, Subcutaneous; Male; Nicotine; Nicotinic Agonists; Pramipexole; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D3; Receptors, Dopamine D5; Substance Withdrawal Syndrome; Tobacco Use Disorder | 2011 |